Segura Sheila E, Ramos-Rivera Gloria, Hakima Laleh, Suhrland Mark, Khader Samer
Pathology Department, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
Cytopathology. 2019 Jan;30(1):99-104. doi: 10.1111/cyt.12629. Epub 2018 Oct 12.
The 2014 Bethesda System for Reporting Cervical Cytology classifies squamous intraepithelial lesions (SILs) of cervix into two main categories: low-grade SIL (LSIL) and high-grade SIL (HSIL). In some clinical practices, the LSIL cannot rule out high-grade lesion (LROH) interpretive category is used in cases with LSIL and findings that may raise the possibility of HSIL. Our purpose is to assess follow-up histopathology and high-risk human papillomavirus (hrHPV) results in patients with LROH, in comparison with LSIL, atypical squamous cells, cannot rule out HSIL (ASC-H), and HSIL in our institution.
Cervical Papanicolaou tests with LROH, LSIL, ASC-H and HSIL interpretation, surgical follow-up, and hrHPV status were retrieved from the computer database from May 2014 to December 2016.
Of 109 963 total Papanicolaou tests, LROH comprised 0.3%, LSIL 3.1%, ASC-H 0.2% and HSIL 0.4%. Only 3272 cases with surgical diagnoses were included in the study. The most common histological outcome for ASC-H was cervical intraepithelial neoplasia (CIN)2/3 (32.6%); LSIL was CIN 1 (45.7%); LROH was CIN 1 (46.7%) and HSIL was CIN 2/3 (64.4%). For LROH and LSIL, 31.1% and 7.5% respectively, had CIN 2/3. Approximately 79% of cases were hrHPV positive. Of LROH cases with surgical follow-up, 86.9% tested hrHPV positive, accounting for the second most common positive group after HSIL (92.6%).
In our study cohort, LROH interpretation is associated with a higher number of CIN 2 or higher lesions on follow-up compared to patients with LSIL (P < 0.0001), and is associated with a significant percentage of positive other hrHPV, supporting LROH as a useful diagnostic category that triggers appropriate follow-up in affected women.
2014年《贝塞斯达系统报告宫颈细胞学》将宫颈鳞状上皮内病变(SILs)分为两大类:低级别SIL(LSIL)和高级别SIL(HSIL)。在一些临床实践中,对于LSIL且有发现可能提示HSIL可能性的病例,使用LSIL不能排除高级别病变(LROH)的解读类别。我们的目的是评估在本机构中,与LSIL、非典型鳞状细胞不能排除HSIL(ASC-H)和HSIL患者相比,LROH患者的后续组织病理学和高危型人乳头瘤病毒(hrHPV)检测结果。
检索2014年5月至2016年12月计算机数据库中具有LROH、LSIL、ASC-H和HSIL解读的宫颈巴氏试验、手术随访情况及hrHPV状态。
在总共109963例巴氏试验中,LROH占0.3%,LSIL占3.1%,ASC-H占0.2%,HSIL占0.4%。本研究仅纳入3272例有手术诊断的病例。ASC-H最常见的组织学结果是宫颈上皮内瘤变(CIN)2/3(32.6%);LSIL是CIN 1(45.7%);LROH是CIN 1(46.7%),HSIL是CIN 2/3(64.4%)。对于LROH和LSIL,分别有31.1%和7.5%有CIN 2/3。约79%的病例hrHPV呈阳性。在有手术随访的LROH病例中,86.9%检测hrHPV呈阳性,是仅次于HSIL(92.6%)的第二常见阳性组。
在我们的研究队列中,与LSIL患者相比,LROH解读与随访时更高数量的CIN 2或更高级别病变相关(P < 0.0001),并且与相当比例的其他hrHPV阳性相关,这支持LROH作为一个有用的诊断类别,能促使对受影响女性进行适当随访。